Filing Flows › Nuvation Bio (NUVB) › Q3 2026 › vs Q3 2025
Nuvation Bio (NUVB) Q3 2026 vs Q3 2025 (year over year)
Nuvation Bio's revenue rose $31.8M (+243%) from $13.1M in Q3 2025 to $45.0M in Q3 2026. The biggest changes: Product Revenue +$19.8M (+257%); License +$12.1M (+224%).
Nuvation Bio, Q3 2026: revenue $45.0M (+243% year over year), operating margin -93.9%, net loss $41.9M, operating cash flow −$38.6M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product Revenue | $27.5M | $7.7M | $19.8M | +257% |
| License | $17.5M | $5.4M | $12.1M | +224% |
| Revenue | $45.0M | $13.1M | $31.8M | +243% |
| Other income, net | $311K | $642K | −$331K | -52% |
| Net loss | $41.9M | $55.8M | −$13.9M | -25% |
| Costs & expenses | $87.2M | $69.6M | $17.6M | +25% |
| Operating costs | $87.2M | $69.6M | $17.6M | +25% |
| Research & development | $32.7M | $28.8M | $3.8M | +13% |
| SG&A | $42.6M | $37.4M | $5.2M | +14% |
| Operating cash sources | $49.2M | $61.4M | −$12.2M | -20% |
| Depreciation & amortization | $578K | $534K | $44K | +8% |
| Share-based compensation | $10.1M | $8.0M | $2.0M | +26% |
| Cash used in operations | $38.6M | $52.9M | −$14.3M | -27% |
| Net loss absorbed | $41.9M | $55.8M | −$13.9M | -25% |
| Working capital & other | $7.3M | $5.7M | $1.7M | +29% |
Questions
How much did Nuvation Bio's revenue grow year over year in Q3 2026?
Nuvation Bio's revenue rose $31.8M (+243%) from $13.1M in Q3 2025 to $45.0M in Q3 2026.
What drove Nuvation Bio's revenue change in Q3 2026?
Product Revenue +$19.8M (+257%); License +$12.1M (+224%).